Last reviewed · How we verify

Fitusiran (SAR439774) — Competitive Intelligence Brief

Fitusiran (SAR439774) (Fitusiran (SAR439774)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: RNA interference (RNAi) therapeutic; antithrombin silencer. Area: Hematology.

marketed RNA interference (RNAi) therapeutic; antithrombin silencer Antithrombin (AT) mRNA Hematology Small molecule Live · refreshed every 30 min

Target snapshot

Fitusiran (SAR439774) (Fitusiran (SAR439774)) — Genzyme, a Sanofi Company. Fitusiran is an RNA interference (RNAi) therapeutic that silences antithrombin (AT) messenger RNA to reduce antithrombin levels and enhance the intrinsic coagulation pathway, thereby increasing thrombin generation in patients with hemophilia.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Fitusiran (SAR439774) TARGET Fitusiran (SAR439774) Genzyme, a Sanofi Company marketed RNA interference (RNAi) therapeutic; antithrombin silencer Antithrombin (AT) mRNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (RNA interference (RNAi) therapeutic; antithrombin silencer class)

  1. Genzyme, a Sanofi Company · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Fitusiran (SAR439774) — Competitive Intelligence Brief. https://druglandscape.com/ci/fitusiran-sar439774. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: